Havens, Courtney G.

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate Tcells by inducing degradation of Tcell repressors Ikaros and Aiolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN

Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 619

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Hansen, J. D., Correa, M., Nagy, M. A., Alexander, M., Plantevin, V., Grant, V., Whitefield, B., Huang, D., Kercher, T., Harris, R., et al. (2020) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 240

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Bjorklund, C. C., Lu, L., Kang, J., Hagner, P. R., Havens, C. G., Amatangelo, M., Wang, M., Ren, Y., Couto, S., Breider, M., et al. (2015) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 221

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 203

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Lopez-Girona, A., Havens, C. G., Lu, G., Rychak, E., Mendy, D., Gaffney, B., Surka, C., Lu, C.-C., Matyskiela, M., Khambatta, G., et al. (2019) · Blood

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 25